Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
Similar Posts
Early Alert: Glucose Monitor Sensor Issue from Abbott Diabetes Care
Certain Abbott Diabetes Care Continuous Glucose Monitor sensors may provide incorrect low glucose readingsDeVere Manufacturing Inc. – 715846 – 11/12/2025
CGMP/Finished Pharmaceuticals/AdulteratedEarly Alert: Broselow Rainbow Tape Issue from AirLife
AirLife is removing Broselow Rainbow Tapes due to incorrectly printed medication dosing information.Accelerated Approval Program
To allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpointNew England Home Therapies Inc. Southborough, MA. 483 Issued 01/27/2016
Record Date 01/27/2016
FEI Number 1000120535
Firm Name New England Home Therapies Inc.
Record Type 483
State MA
Establishment Type Producer of Sterile Drug ProductsFDA approves new treatment for acromegaly, a rare endocrine disorder
The U.S. Food and Drug Administration (FDA) approved Palsonify (paltusotine) tablets to treat adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.